Sculptra^®-Related Complication in Tear-Trough Treatment-A Case Report

Background: Sculptra^®, a product of poly-L-lactic acid, has been used widely in Europe since 1999, and gained U.S. Food and Drug Administration approval for use in human immunodeficiency virus-related facial lipoatrophy in August 2004. This stimulatory filler was then developed for use in other types of facial-filler procedures in Taiwan. A 30-year-old woman who received Sculptra^® injection for depressed tear-trough grooves complained of both nodular formation and ectropion for two years. We removed the filler, and here we discussed its effect. Materials and Methods: A 30-year-old woman received Sculptra^® injection for 2 years, but nodule formation was prominent. We discuss the management of and complications associated with this filler. Results: Surgery for removal of the filler was performed under general anesthesia. A transconjunctival approach was used to remove foreign bodies, and pathological analysis was achieved. The patient was satisfied with the final outcome. Conclusion: Sculptra^® is widely used for facial lipodystropy. Physicians should focus closely on periorbital injection because complications will be troublesome and disturbing. Surgery should be the ultimate but effective method for management.